Literature DB >> 12203874

Fine-needle aspiration biopsy of the retroperitoneum: a series of 111 cases not including specific organs.

Fernando López-Ríos1, Andrés Pérez-Barrios, Nuria Alberti, Javier Vargas, Francisco Lozano, Pedro de Agustín.   

Abstract

We report on our experience in fine-needle aspiration (FNA) biopsy of the retroperitoneum: 111 FNA biopsies performed on 99 patients. Cytologic diagnoses were divided into four groups: nondiagnostic (unsatisfactory samples because of a low cellularity and/or improperly prepared smears) aspirates (20%), benign (16%), suspicious for malignancy (13%), and malignant (50%). There were no known false-positive samples. We had two false-negative diagnoses due to sampling errors. Among diagnostic smears, the procedure showed a sensitivity of 97% and a specificity of 100%. The predictive value of a positive result was 100% and the predictive value of a negative result was 90%. The overall accuracy was 98%. Metastatic carcinomas accounted for the largest number of lesions in the group of malignant tumors. A primary tumor site was known for the majority of the cases before the aspiration was performed. In the remaining cases we were unable to suggest an origin. It is therefore important to emphasize the role of ancillary studies in patients that are at the first assessment of the disease or when a second intercurrent malignancy is suspected. In our limited experience, a suggestion of the correct subtype of retroperitoneal sarcoma was not possible. As in the rest of cytopathology, a multidisciplinary approach is mandatory in this setting to improve patient management. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12203874     DOI: 10.1002/dc.10149

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  1 in total

1.  Benefits of 3D technique in guiding percutaneous retroperitoneal biopsies.

Authors:  M De Filippo; F Gira; D Corradi; N Sverzellati; M Zompatori; C Rossi
Journal:  Radiol Med       Date:  2011-02-10       Impact factor: 3.469

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.